Home BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting
 

Keywords :   


BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting

2014-09-07 03:43:00| Biotech - Topix.net

BioCryst Pharmaceuticals, Inc. today announced trial results related to RAPIVAB , a neuraminidase inhibitor for the treatment of influenza at the Interscience Conference on Antimicrobial Agents & Chemotherapy in Washington, D.C., September 5-9, 2014. "Based on clinical trial data, peramivir is the first neuraminidase inhibitor that has shown to be safe and effective as a single-dose therapy for patients with acute, uncomplicated influenza," said presenting author Richard Whitley, M.D , University of Alabama at Birmingham.

Tags: the results meeting treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11PM responds to Sir Alan Bates after repeated requests
05.11American Angus elects 2024-25 board leaders
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 8A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Brazil gives green light to medicinal use of Cannabis in animals
More »